Showing results (11-20 of 205) with videos related to
Sort By:
Pageof 21
Current Drug Targets. CNS and Neurological Disorders|May 29, 2003
Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosisC A Tamminga, A CarlssonJournal of Neural Transmission. General Section|January 1, 1995
MK801 induces late regional increases in NMDA and kainate receptor binding in rat brainX M Gao, C A TammingaNeuroscience Letters|June 20, 1994
An increase in NMDA-sensitive [3H]glutamate and [3H]kainate binding in hippocampus 24 hours after PCPX M Gao, C A TammingaArchives of Neurology|April 1, 1980
Bromocriptine and CF 25-397 in the treatment of tardive dyskinesiaC A Tamminga, T N ChaseAmerican Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|February 1, 1995
Recent developments in the neuropharmacology of schizophreniaA C Lahti, C A TammingaDialogues in Clinical Neuroscience|October 29, 2011
The biology of schizophreniaC A Tamminga, D R MedoffInternational Clinical Psychopharmacology|May 1, 1996
The new generation of antipsychotic drugsC A Tamminga, A C LahtiProgress in Neuro-Psychopharmacology & Biological Psychiatry|December 3, 1999
Effect of amphetamine, alpha-methyl-p-tyrosine (alpha-MPT) and antipsychotic agents on dopamine D2-type receptor occupancy in ratsR A Lahti, C A TammingaMolecular Psychiatry|September 2, 2004
Phenotype of schizophrenia: a review and formulationC A Tamminga, H H HolcombThe Journal of Nervous and Mental Disease|December 1, 1982
The DSM-III diagnosis of schizophrenic-like illness and the clinical pharmacology of psychosisC A Tamminga, W T CarpenterPageof 21